Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00075400 · OUTCOME

Initial Performance Status

Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer · Source last updated 2019-07-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Baseline

What was measured

Performance Status 0 = Fully active, able to carry on all pre-disease performance without restriction Performance Status 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of light or sedentary nature, e.g., light housework, office work Performance Status 2 = Ambulatory and capable of all self care but unable to carry out any work activities. Up and about more than 50% of waking hours.

Analysis population: Eligible and treated patients

Groups in this outcome

Gleevec

Gleevec™ 600 mg QD po continuously (a cycle will be defined as 28 days). If first cycle of Gleevec™ at 600 mg QD is tolerated without any significant toxicity, the dose can be escalated to 400 mg BID po Q 12 hours until disease progression or adverse effects prohibit further therapy.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Gleevec23

Reported measurements

Source class 1

Performance status 0

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Gleevec12Not reportedNot reportedNot reportedNot reported

Performance status 1

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Gleevec10Not reportedNot reportedNot reportedNot reported

Performance status 2

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Gleevec1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        12
      title
      Performance status 0
    2. measurements
      1. group Id
        OG000
        value
        10
      title
      Performance status 1
    3. measurements
      1. group Id
        OG000
        value
        1
      title
      Performance status 2
denoms
  1. counts
    1. group Id
      OG000
      value
      23
    units
    Participants
description
Performance Status 0 = Fully active, able to carry on all pre-disease performance without restriction Performance Status 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of light or sedentary nature, e.g., light housework, office work Performance Status 2 = Ambulatory and capable of all self care but unable to carry out any work activities. Up and about more than 50% of waking hours.
groups
  1. description
    Gleevec™ 600 mg QD po continuously (a cycle will be defined as 28 days). If first cycle of Gleevec™ at 600 mg QD is tolerated without any significant toxicity, the dose can be escalated to 400 mg BID po Q 12 hours until disease progression or adverse effects prohibit further therapy.
    id
    OG000
    title
    Gleevec
param Type
COUNT_OF_PARTICIPANTS
population Description
Eligible and treated patients
reporting Status
POSTED
time Frame
Baseline
title
Initial Performance Status
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice